Contribute Try STAT+ Today

Top of the morning to you. Gray skies are hovering over the Pharmalot campus right now, but our spirits remain sunny, nonetheless. Why? We will trot out a bit of insight from the Morning Mayor, who would say, “Every new day should be unwrapped like a precious gift.” To celebrate the notion, we are brewing still more cups of stimulation and invite you to join us. Our choice today, for those tracking this sort of thing, is … mountain blueberry. Meanwhile, here are a few items of interest. We hope your journey progresses nicely today and that you remain safe — remember, wear a mask….

Novartis (NVS) will help manufacture a Covid-19 vaccine that CureVac (CVAC) is developing, the latest drug maker tie-up aimed at accelerating production of shots, The Wall Street Journal notes. The two-dose vaccine is in late-stage testing and results could come as soon as next month. Novartis will upgrade a plant in Kundl, Austria, so it can help make up to 50 million doses of the vaccine this year and up to 200 million doses next year. Production is expected to begin in the second quarter, and delivery of key components in the summer.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.